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The prognosis of patients with early relapsed or refractory large B-cell lymphoma
after the receipt of first-line chemoimmunotherapy is poor.
METHODS

In this international, phase 3 trial, we randomly assigned, in a 1:1 ratio, patients
with large B-cell lymphoma that was refractory to or had relapsed no more than
12 months after first-line chemoimmunotherapy to receive axicabtagene ciloleucel
(axi-cel, an autologous anti-CD19 chimeric antigen receptor T-cell therapy) or
standard care (two or three cycles of investigator-selected, protocol-defined chemo
immunotherapy, followed by high-dose chemotherapy with autologous stem-cell
transplantation in patients with a response to the chemoimmunotherapy). The
primary end point was event-free survival according to blinded central review. Key
secondary end points were response and overall survival. Safety was also assessed.
RESULTS

A total of 180 patients were randomly assigned to receive axi-cel and 179 to receive
standard care. The primary end-point analysis of event-free survival showed that
axi-cel therapy was superior to standard care. At a median follow-up of 24.9
months, the median event-free survival was 8.3 months in the axi-cel group and
2.0 months in the standard-care group, and the 24-month event-free survival was
41% and 16%, respectively (hazard ratio for event or death, 0.40; 95% confidence
interval, 0.31 to 0.51; P<0.001). A response occurred in 83% of the patients in the
axi-cel group and in 50% of those in the standard-care group (with a complete
response in 65% and 32%, respectively). In an interim analysis, the estimated
overall survival at 2 years was 61% in the axi-cel group and 52% in the standardcare group. Adverse events of grade 3 or higher occurred in 91% of the patients
who received axi-cel and in 83% of those who received standard care. Among
patients who received axi-cel, grade 3 or higher cytokine release syndrome occurred in 6% and grade 3 or higher neurologic events in 21%. No deaths related
to cytokine release syndrome or neurologic events occurred.
CONCLUSIONS

Axi-cel therapy led to significant improvements, as compared with standard care,
in event-free survival and response, with the expected level of high-grade toxic
effects. (Funded by Kite; ZUMA-7 ClinicalTrials.gov number, NCT03391466.)
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S

tandard-care second-line treatment in the curative setting for patients
with relapsed or refractory large B-cell
lymphoma is high-dose chemotherapy with autologous stem-cell transplantation if the disease
is responsive to salvage chemoimmunotherapy.1-3
Certain disease characteristics, such as primary
refractoriness, a high second-line age-adjusted
International Prognostic Index (IPI), and doubleor triple-hit genetic lesions in the tumor (re
arrangement of MYC with BCL2 or BCL6 [or both]),
limit the likelihood of response.4,5 Patients whose
disease does not respond to salvage chemotherapy and those who are not considered to be
candidates for high-dose chemotherapy with
autologous stem-cell transplantation have poor
outcomes.4,6,7 These patients may benefit from
second-line therapies that have different mechanisms of action.
The autologous anti-CD19 chimeric antigen
receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) is approved for the treatment of
patients with relapsed or refractory large B-cell
lymphoma who have received at least two previous systemic therapies.8,9 In the ZUMA-1 trial,
which involved patients with refractory large B-cell
lymphoma treated with axi-cel, 83% of the patients had a response and 58% had a complete
response10; the median overall survival was 25.8
months, and the 5-year overall survival was
43%.11 Thus, we conducted ZUMA-7, an international, randomized, phase 3 trial comparing axicel with standard care as second-line treatment
in patients with early relapsed or refractory large
B-cell lymphoma. We report here the results of
the primary and key secondary analyses.

Me thods
Trial Design and Oversight

We conducted this trial at 77 sites worldwide
(see the Supplementary Appendix, available with
the full text of this article at NEJM.org). Eligible
patients were at least 18 years of age and had
histologically confirmed large B-cell lymphoma,
according to the World Health Organization
2016 classification criteria,12 that was refractory
to first-line treatment or that had relapsed from
complete remission no more than 12 months
after the completion of first-line chemoimmunotherapy including an anti-CD20 monoclonal antibody and anthracycline-containing regimen;
n engl j med 386;7

patients intended to proceed to high-dose chemotherapy with autologous stem-cell transplantation. Refractory disease was defined as a lack of
complete response to first-line therapy, and relapsed disease as biopsy-proven disease relapse
occurring no more than 12 months after the
completion of first-line therapy.
All the patients provided written informed consent. After institutional review board approval of
the trial protocol (available at NEJM.org), the
trial was conducted in compliance with the principles of the Declaration of Helsinki. Kite, a
Gilead company (the trial sponsor), and the authors collaborated on the trial design and the
data collection, analysis, and interpretation. The
first draft was written by the first and last authors, with medical writing assistance funded
by the sponsor. All the authors contributed to
the writing of the manuscript and vouch for the
accuracy and completeness of the data and for
the adherence of the trial to the protocol. The
authors were under a confidentiality agreement
and had data access after trial unblinding.
After screening, patients underwent randomization in a 1:1 ratio to receive axi-cel or investigator-selected standard-care chemoimmunotherapy. Randomization was stratified according to
response to first-line therapy (refractory vs. relapsed disease) and the second-line age-adjusted
IPI (0 or 1 risk factor [indicating low or intermediate risk] vs. 2 or 3 risk factors [indicating high
risk]). Patients in the axi-cel group underwent
leukapheresis, followed by conditioning chemotherapy with cyclophosphamide (at a dose of
500 mg per square meter of body-surface area
per day) and fludarabine (30 mg per square meter
per day) at −5, −4, and −3 days before receiving
a single infusion of axi-cel (target dose, 2×106
CAR T cells per kilogram of body weight). Optional bridging therapy was limited to glucocorticoids only. Patients in the standard-care group
received two or three cycles of protocol-defined,
investigator-selected, platinum-based chemoimmunotherapy. Patients who had a complete or
partial response proceeded to high-dose chemotherapy with autologous stem-cell transplantation. Although crossover between the treatment
groups was not planned, patients who did not
have a response to standard care could receive
cellular immunotherapy outside the protocol
(treatment switching). Management guidelines
for CAR T-cell–related adverse events followed
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that used in cohorts 1 and 2 of ZUMA-1.13 The
severity of the cytokine release syndrome was
graded according to the modified criteria of Lee
et al.14 Adverse events, including symptoms related to the cytokine release syndrome and neurologic events, were graded according to the Common Terminology Criteria for Adverse Events,
version 4.03, of the National Cancer Institute.
End Points and Assessments

The primary end point was event-free survival
(defined as the time from randomization to the
earliest date of disease progression according to
the Lugano classification,15 the commencement
of new therapy for lymphoma, death from any
cause, or a best response of stable disease up to
and including the response on the day 150 assessment after randomization) according to blinded central review. Key secondary end points were
response and overall survival. Secondary end
points included event-free survival as assessed by
the investigator, progression-free survival (defined as the time from randomization to disease
progression or death from any cause), and the
incidence of adverse events. Exploratory end
points included blood CAR T-cell levels (in the
axi-cel group). Disease assessments occurred on
days 50, 100, and 150 after randomization, followed by every 3 months until 2 years of followup, and then every 6 months until 5 years of
follow-up. Patient-reported outcomes were assessed but are not reported here.
Statistical Analysis

The protocol-specified primary efficacy analysis
was to be conducted when 250 events, as assessed by blinded central review, had occurred.
We calculated that this number of events would
provide the trial with approximately 90% power
at a one-sided 2.5% significance level to detect
event-free survival that was 50% longer in the
axi-cel group than in the standard-care group.
Patients who did not meet the event criteria had
their data censored; disease progression events
and censoring times were determined on the basis of blinded central review. A subgroup analysis
of event-free survival was conducted for prespecified covariates.
Statistical testing of the primary and key secondary end points was conducted hierarchically.
Event-free survival was tested first; conditional
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on significantly longer event-free survival being
observed in the axi-cel group than in the standard-care group, response was tested at the 2.5%
level at the time of the primary analysis of eventfree survival. Conditional on significantly longer
event-free survival and a significantly higher percentage of patients with a response being observed in the axi-cel group than in the standardcare group, overall survival was to be tested up
to three times, according to the rho-family spending function, at an overall alpha level of 2.5%.
An interim analysis of overall survival, reported
here, occurred at the time of the primary analysis. A prespecified sensitivity analysis of overall
survival was conducted to adjust for the confounding effect of treatment switching from
standard care to cellular immunotherapy.
Efficacy analyses were conducted according
to the intention-to-treat principle and included
all the patients who underwent randomization.
Safety analyses included all the patients who
underwent randomization and received at least
one dose of axi-cel or standard-care therapy according to the protocol; patients were analyzed
according to the protocol therapy they received.
The safety population for autologous stem-cell
transplantation comprised the patients who underwent autologous stem-cell transplantation according to the protocol.
Kaplan–Meier estimates were provided for timeto-event end points. Estimated hazard ratios
with two-sided 95% confidence intervals were
calculated from a Cox proportional-hazards
model with stratification according to the randomization stratification factors. Stratified logrank P values (two-sided) were calculated for
time-to-event end points. A stratified Cochran–
Mantel–Haenszel test was performed for analysis of response. Details of the statistical analysis
are provided in the Supplementary Appendix.

R e sult s
Patients

Of the 437 patients screened, 359 underwent
randomization between January 25, 2018, and
October 4, 2019; a total of 180 patients were
assigned to the axi-cel group and 179 to the
standard-care group (Fig. 1). As of March 18,
2021, the median follow-up from randomization
to the data-cutoff date was 24.9 months. The
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median age of the patients was 59 years; 30% of
the patients were 65 years of age or older. A total
of 74% of the patients had primary refractory disease, 45% had a high second-line age-adjusted
IPI (2 or 3 risk factors), 54% had an elevated
lactate dehydrogenase level, 79% had stage III or
IV disease, and 19% had high-grade B-cell lymphoma (including double- or triple-hit lymphomas) according to the investigator’s assessment
(Table 1). The characteristics of the patients at
baseline were generally balanced between the
two treatment groups and were consistent with
those expected in persons with relapsed or refractory diffuse large B-cell lymphoma (Table S1
in the Supplementary Appendix).
Among the patients in the axi-cel group, 178
(99%) underwent leukapheresis and 170 (94%)
received axi-cel; 65 patients (36%) received bridging therapy with glucocorticoids. Axi-cel was
successfully manufactured for all the patients
who underwent leukapheresis (see the Supplementary Results section). Among the 170 patients who received axi-cel, the median time
from leukapheresis to product release (i.e., when
the product passed quality testing and was made
available to the investigator) was 13 days. Among
the patients in the standard-care group, 168
(94%) received platinum-based salvage chemotherapy, and 64 (36%) received high-dose chemotherapy and underwent autologous stem-cell
transplantation (including 2 patients who underwent autologous stem-cell transplantation outside the protocol) (Fig. 1 and Tables S2 and S3).
Efficacy

The median event-free survival according to
blinded central review was significantly longer
in the axi-cel group (8.3 months; 95% confidence interval [CI], 4.5 to 15.8) than in the
standard-care group (2.0 months; 95% CI, 1.6 to
2.8) (Fig. 2A). The estimated event-free survival
at 24 months was 41% (95% CI, 33 to 48) in the
axi-cel group, as compared with 16% (95% CI,
11 to 22) in the standard-care group (Table S4).
The event-free survival curves show that treatment with axi-cel was superior to standard care
(hazard ratio for event or death, 0.40; 95% CI,
0.31 to 0.51; P<0.001). The improvements in
event-free survival with axi-cel as compared with
standard care were consistent in all prespecified
key subgroups (Fig. 2B).

n engl j med 386;7

The percentage of patients with a response in
the axi-cel group was 1.66 times as high as that
in the standard-care group (83% vs. 50%; difference, 33 percentage points; P<0.001) (Figs. S1
and S2). A complete response was observed in
65% of the patients in the axi-cel group and in
32% of those in the standard-care group.
The median overall survival, evaluated as an
interim analysis, was not reached in the axi-cel
group and was 35.1 months in the standard-care
group (hazard ratio for death, 0.73; 95% CI, 0.53
to 1.01; P = 0.054 [two-sided], statistical significance not reached) (Fig. 3A). In the interim
analysis, the estimated overall survival at 2 years
was 61% in the axi-cel group and 52% in the
standard-care group. Overall, 72 patients (40%) in
the axi-cel group and 81 (45%) in the standardcare group died from any cause; 52 patients (29%)
in the axi-cel group and 65 (36%) in the standard-care group died from progressive disease.
A total of 56% of the patients in the standardcare group received subsequent cellular immunotherapy. Results of a prespecified sensitivity
analysis of overall survival, which was conducted
to address the confounding effects of this treatment-switching in the standard-care group,
showed a difference in overall survival in favor
of axi-cel (stratified hazard ratio, 0.58; 95% CI,
0.42 to 0.81) with the rank-preserving structural
failure time method. An additional analysis,
which was conducted with the use of the inverse
probability of censoring weights model, showed
a stratified hazard ratio of 0.70 (95% CI, 0.46 to
1.05) (Fig. S3).
The median progression-free survival was
14.7 months (95% CI, 5.4 to could not be estimated) in the axi-cel group and 3.7 months
(95% CI, 2.9 to 5.3) in the standard-care group
(hazard ratio for progression or death, 0.49;
95% CI, 0.37 to 0.65) (Fig. 3B). The estimated
progression-free survival at 24 months was 46%
(95% CI, 38 to 53) in the axi-cel group and 27%
(95% CI, 20 to 35) in the standard-care group.
Safety

All the patients had at least one adverse event of
any grade. Adverse events of grade 3 or higher
occurred in 155 of 170 patients (91%) who received axi-cel and in 140 of 168 patients (83%)
who received standard care. The most commonly
reported adverse event of grade 3 or higher was
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437 Patients were assessed for eligibility
78 Had screening failure
69 Did not meet eligibility criteria
4 Were withdrawn by investigator
5 Had other reason
359 Were enrolled and underwent
randomization

180 Were assigned to axi-cel group

179 Were assigned to standard-care group

11 Did not receive standard care
8 Declined to participate
1 Was lost to follow-up
2 Had other reason

2 Did not undergo leukapheresis
1 Had progressive disease
1 Had other reason

168 Received ≥1 dose of salvage
chemotherapy

178 Underwent leukapheresis

88 Did not continue trial
56 Had progressive disease
27 Had stable disease
1 Had adverse event
4 Had other reason

6 Did not receive lymphodepleting
chemotherapy
2 Had adverse event
2 Died
1 Had progressive disease
1 Had other reason

80 Had response to salvage chemotherapy
11 Did not undergo leukapheresis
9 Had progressive disease
1 Had adverse event
1 Had insufficient response
to proceed to ASCT
69 Had response to salvage chemotherapy
and underwent leukapheresis
5 Did not receive HDT owing
to progressive disease

172 Received lymphodepleting
chemotherapy

64 Received HDT
2 Did not receive per-protocol
CD34+ stem-cell rescue
therapy
1 Had progressive disease
1 Had other reason

2 Did not receive axi-cel infusion
owing to adverse event

62 Received per-protocol CD34+
stem-cell rescue therapy

170 Received axi-cel infusion

180 Were included in the efficacy analysis
170 Were included in the safety analysis
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168 Were included in the safety analysis
62 Were included in the ASCT safety
analysis
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adverse events of any grade occurred in 50% of
the patients who received axi-cel and in 46% of
those who received standard care (Table S5).
Various infections of any grade occurred in 41%
of the patients who received axi-cel and in 30%
of those who received standard care, with infections of grade 3 or higher occurring in 14% and
11%, respectively.
The frequency of cytopenias is summarized
in Table 2. Prolonged cytopenias of grade 3 or
higher that were present at or after 30 days after
the initiation of definitive therapy (i.e., from
receipt of the axi-cel infusion or first dose of
high-dose chemotherapy) occurred in 49 patients (29%) who received axi-cel and in 12 of 62
patients (19%) in the standard-care group who
underwent per-protocol autologous stem-cell
transplantation (Table S6). No cases of replication-competent retrovirus infection or axi-cel
treatment–related secondary cancer were reported. Hypogammaglobulinemia during treatment occurred in 11% of the patients who received axi-cel and in 1% of those who received
standard care; all the events were grade 1 or 2
(Table S7). Among 160 patients who received
axi-cel and were tested for B-cell aplasia, 47%
had B-cell aplasia up to 6 months after the infusion and 36% did so up to 12 months after the
infusion (Table S8). Utilization of the intensive
care unit is summarized in the Supplementary
Results section.
Fatal adverse events occurred in 7 patients
(4%) in the axi-cel cohort (of which only one
event [hepatitis B virus reactivation] was considered by the investigators to be related to axi-cel)
and in 2 patients (1%) in the standard-care cohort (both events [cardiac arrest and acute respiratory distress syndrome] were considered by the
investigators to be related to high-dose chemotherapy) (Table S9).
Cytokine release syndrome occurred in 157
patients (92%) who received axi-cel (Table 2),
with an event of grade 3 or higher occurring in
11 patients (6%). No deaths related to cytokine
release syndrome occurred. In the safety population, tocilizumab was administered to 65% of
the patients, glucocorticoids to 24%, and vasopressors to 6%. The median cumulative use of
tocilizumab, regardless of indication, was 1396 mg
neutropenia, which occurred in 69% of the pa- (range, 430 to 7200). The median time to the
tients who received axi-cel and in 41% of those onset of cytokine release syndrome was 3 days
who received standard care (Table 2). Serious (range, 1 to 10) after the infusion, and the meFigure 1 (facing page). Randomization, Treatment,
and Follow-up of the Patients.
Five patients did not pass screening owing to insurance
issues (in 3), rapid disease progression (in 1), and decision to opt out (in 1). The efficacy analysis population
included all the patients who underwent randomization;
the safety analysis population included all the patients
who underwent randomization and received at least one
dose of axicabtagene ciloleucel (axi-cel) or standardcare chemotherapy as protocol therapy. The safety analysis population for autologous stem-cell transplantation
(ASCT) included all the patients in the standard-care
group who underwent ASCT as part of protocol therapy.
In the axi-cel group, 1 patient did not undergo leukapheresis owing to ineligibility. Adverse events that precluded lymphodepleting chemotherapy included an increase
in the alanine aminotransferase level and hyperbilirubinemia (in 1 patient each); in addition, 1 patient had
false progression at baseline, and reassessment showed
no progression. Adverse events that precluded receipt
of an axi-cel infusion included cerebrovascular accident
and small intestinal perforation (in 1 patient each).
Standard-care chemotherapy regimens included R-ICE
(rituximab, ifosfamide, carboplatin, and etoposide), R-GDP
(rituximab, gemcitabine, dexamethasone, and cisplatin
[or carboplatin]), R-DHAP or R-DHAX (rituximab, dexamethasone, high-dose cytarabine, and cisplatin or oxaliplatin), and R-ESHAP (rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin) (Table S3).
One patient did not receive therapy owing to a negative
disease biopsy, and 1 had a false positive result on positron-emission tomography–computed tomography and
did not have refractory double-hit lymphoma after five
cycles of R-EPOCH (rituximab, etoposide, prednisone,
vincristine, cyclophosphamide, and doxorubicin). Response to salvage chemotherapy was determined by
the investigator, with progressive disease being defined
here as a best response of progressive disease or disease progression after an initial response to salvage
chemotherapy. Four patients with a best response of
progressive disease and 1 with stable disease underwent leukapheresis but did not proceed further in the
trial, and 1 had an adverse event of acute kidney injury.
Four patients did not proceed further owing to lack of
response to salvage chemoimmunotherapy with R-ICE,
an inability to receive R-GDP owing to adverse events
and a subsequent switch to R-ICE, a change of treatment after one cycle of R-DHAP owing to renal impairment, and insufficient overall response to proceed to
ASCT (in 1 patient each). One patient had an adverse
event of blood stem-cell harvest failure and did not undergo leukapheresis. One patient was inadvertently enrolled on an alternate protocol and did not receive CD34+
stem-cell rescue therapy per protocol. HDT denotes
high-dose chemotherapy.
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Table 1. Demographic and Clinical Characteristics of the Patients at Baseline.*
Characteristic

Axi-cel
(N = 180)

Standard Care
(N = 179)

Total
(N = 359)

58 (21–80)

60 (26–81)

59 (21–81)

Age
Median (range) — yr
≥65 yr — no. (%)

51 (28)

58 (32)

109 (30)

110 (61)

127 (71)

237 (66)

0

1 (1)

Asian

12 (7)

10 (6)

22 (6)

Black

11 (6)

7 (4)

18 (5)

Male sex — no. (%)
Race or ethnic group — no. (%)†
American Indian or Alaska Native

Native Hawaiian or other Pacific Islander

1 (<1)

2 (1)

1 (1)

3 (1)

White

145 (81)

152 (85)

297 (83)

Other

10 (6)

8 (4)

18 (5)

Yes

10 (6)

8 (4)

18 (5)

No

167 (93)

169 (94)

336 (94)

3 (2)

2 (1)

5 (1)

85 (47)

79 (44)

164 (46)

Hispanic or Latino ethnic group — no. (%)†

Not reported
ECOG performance-status score of 1 — no. (%)‡
Disease stage — no. (%)
I or II
III or IV
Second-line age-adjusted IPI of 2 or 3 — no. (%)§

41 (23)

33 (18)

74 (21)

139 (77)

146 (82)

285 (79)

82 (46)

79 (44)

161 (45)

Molecular subgroup according to central laboratory
— no. (%)¶
Germinal center B-cell–like

109 (61)

99 (55)

208 (58)

Activated B-cell–like

16 (9)

9 (5)

25 (7)

Unclassified

17 (9)

14 (8)

31 (9)

Not applicable

10 (6)

16 (9)

26 (7)

Missing data

28 (16)

41 (23)

69 (19)

133 (74)

131 (73)

264 (74)

47 (26)

48 (27)

95 (26)

126 (70)

120 (67)

246 (69)

Response to first-line therapy at randomization — no. (%)
Primary refractory disease
Relapse at ≤12 mo after the initiation or completion
of first-line therapy
Disease type according to central laboratory — no. (%)
Diffuse large B-cell lymphoma‖

0

1(1)

1 (<1)

High-grade B-cell lymphoma, including rearrangement
of MYC with BCL2 or BCL6 or both

High-grade B-cell lymphoma, not otherwise specified

31 (17)

25 (14)

56 (16)

Not confirmed or missing data

18 (10)

28 (16)

46 (13)

5 (3)

5 (3)

10 (3)

Large B-cell lymphoma, not otherwise specified

110 (61)

116 (65)

226 (63)

T-cell– or histiocyte–rich large B-cell lymphoma

5 (3)

6 (3)

11 (3)

Other
Disease type according to the investigator — no. (%)

646
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Table 1. (Continued.)
Axi-cel
(N = 180)

Characteristic
Epstein–Barr virus–positive diffuse large B-cell lymphoma

Standard Care
(N = 179)

Total
(N = 359)

2 (1)

0

2 (1)

Large-cell transformation from follicular lymphoma

19 (11)

27 (15)

46 (13)

High-grade B-cell lymphoma, including rearrangement
of MYC with BCL2 or BCL6 or both

43 (24)

27 (15)

70 (19)

1 (1)

0

1 (<1)

0

3 (2)

3 (1)

High-grade B-cell lymphoma, double- or triple-hit

31 (17)

25 (14)

56 (16)

Double-expressor lymphoma

57 (32)

62 (35)

119 (33)

Primary cutaneous diffuse large B-cell lymphoma, leg type
Other
Prognostic marker according to central laboratory — no. (%)

MYC rearrangement

15 (8)

7 (4)

22 (6)

Not applicable

74 (41)

70 (39)

144 (40)

Missing data
CD19+ status on immunohistochemical testing — no. (%)**
Bone marrow involvement — no. (%)††
Elevated lactate dehydrogenase level — no. (%)‡‡
Median tumor burden (range) — mm2§§

3 (2)

15 (8)

18 (5)

144 (80)

134 (75)

278 (77)

17 (9)

15 (8)

32 (9)

101 (56)

94 (53)

195 (54)

2123
(181–22,538)

2069
(252–20,117)

2118
(181–22,538)

*	Patients were randomly assigned to receive axicabtagene ciloleucel (axi-cel) or standard care. Percentages may not
total 100 because of rounding.
†	Race and ethnic group were determined by the investigator.
‡	Eastern Cooperative Oncology Group (ECOG) performance-status scores are assessed on a 5-point scale, with a score
of 0 indicating no symptoms and higher scores indicating greater disability. A score of 1 indicates that the patient is
ambulatory but restricted from strenuous activity.
§	Values are the second-line age-adjusted International Prognostic Index (IPI) at randomization, which were similar to
the second-line age-adjusted IPI according to the investigator as entered into the clinical database. The second-line
age-adjusted IPI is used to assess prognostic risk on the basis of various factors after adjustment for patient age and
extranodal status at the time of diagnosis of refractory disease; risk categories are assessed as low (0 factors), intermediate (1 factor), or high (2 or 3 factors).
¶	The molecular subgroup as assessed by the investigator was as follows: germinal center B-cell–like in 96 patients
(53%) in the axi-cel group, 84 (47%) in the standard-care group, and 180 (50%) overall; non–germinal center B-cell–
like in 47 (26%), 54 (30%), and 101 (28%), respectively. The molecular subgroup was not assessed in 37 patients
(21%) in the axi-cel group, 41 (23%) in the standard-care group, and 78 (22%) overall.
‖	The definition of diffuse large B-cell lymphoma according to the central laboratory included cases of incomplete evaluation that were due to inadequate sample amount or sample type, for which further classification of the subtype was
not possible. Diffuse large B-cell lymphoma, not otherwise specified, according to the World Health Organization
2016 definition,12 is also included.
**	CD19 staining was not required for participation in the trial. Testing was conducted by the central laboratory.
††	The data shown were as collected on the diagnosis history case-report form.
‡‡	An elevated lactate dehydrogenase level was defined as a level that was above the upper limit of the normal range
according to the local laboratory.
§§	Tumor burden was determined on the basis of the sum of product diameters of the target lesions, according to the
Cheson criteria,16 and was assessed by the central laboratory.

dian duration was 7 days (range, 2 to 43). All the
events resolved.
Neurologic events occurred in 102 patients
(60%) who received axi-cel and in 33 (20%) who
received standard care; neurologic events of
grade 3 or higher occurred in 36 patients (21%)
and 1 patient (1%), respectively. No deaths re-

n engl j med 386;7

lated to neurologic events occurred. In the axicel group, glucocorticoids were used in 32% of
the patients for the management of neurologic
events. The median time to the onset of neurologic events was 7 days in the axi-cel group and
23 days in the standard-care group, and the
median duration was 9 days and 23 days, respec-
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A Event-free Survival
100

No. of
Patients

Median
Event-free
Survival
(95% CI)

180
179

mo
8.3 (4.5–15.8)
2.0 (1.6–2.8)

Percentage of Patients

90
80
70
60
50

Axi-cel
Standard Care

Axi-cel

40

Stratified hazard ratio for event or death,
0.40 (95% CI, 0.31–0.51)
P<0.001

30
Standard care

20
10
0

0

2

4

6

8

10

12

14

16

18

20

22

24

26

28

30

32

34

52
20

40
12

26
9

12
7

12
6

6
3

1

0

Month
No. at Risk
Axi-cel
Standard care

180 163 106 92
179 86 54 45

91
38

87
32

85
29

82
27

74
25

67
24

B Subgroup Analysis
Subgroup

Axi-cel

Standard Care

Hazard Ratio for Event or Death
(95% CI)

no. of patients with event/total no.
Overall
108/180
Age
<65 yr
81/129
≥65 yr
27/51
Response to first-line therapy at randomization
Primary refractory disease
85/133
Relapse ≤12 mo after initiation or completion
23/47
of first-line therapy
Second-line age-adjusted IPI
0 or 1
54/98
2 or 3
54/82
Prognostic marker according to central laboratory
HGBL, double- or triple-hit
15/31
Double-expressor lymphoma
35/57
Molecular subgroup according to central laboratory
Germinal center B-cell–like
64/109
Activated B-cell–like
11/16
Unclassified
8/17
Disease type according to investigator
DLBCL, not otherwise specified
68/110
Large-cell transformation from follicular lymphoma
10/19
HGBL, including rearrangement of MYC with BCL2 or BCL6 or both 23/43
Disease type according to central laboratory
DLBCL
79/126
HGBL, including rearrangement of MYC with BCL2 or BCL6 or both 15/31

144/179

0.40 (0.31–0.51)

96/121
48/58

0.49 (0.36–0.67)
0.28 (0.16–0.46)

106/131
38/48

0.43 (0.32–0.57)
0.34 (0.20–0.58)

73/100
71/79

0.41 (0.28–0.58)
0.39 (0.27–0.56)

21/25
50/62

0.28 (0.14–0.59)
0.42 (0.27–0.67)

80/99
9/9
12/14

0.41 (0.29–0.57)
0.18 (0.05–0.72)
—

97/116
24/27
18/27

0.37 (0.27–0.52)
0.35 (0.16–0.77)
0.47 (0.24–0.90)

95/120
21/26

0.44 (0.32–0.60)
0.28 (0.14–0.59)

0.01

0.1 0.2

0.5 1.0 2.0

5.0

Axi-cel Better Standard Care Better

tively. At the time of data cutoff, 2 patients had
ongoing neurologic events; 1 patient who received axi-cel had grade 2 paresthesia and grade
1 memory impairment, and 1 who received standard care had grade 1 paresthesia.
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CAR T-Cell Levels

The median time to peak CAR T-cell levels was
7 days (range, 2 to 233) after the axi-cel infusion
(Table S10 and Fig. S5). The median peak CAR
T-cell level was 25.84 cells per cubic millimeter,
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Figure 2 (facing page). Event-free Survival.
Panel A shows the Kaplan–Meier estimate of event-free
survival (defined as the time from randomization to the
earliest date of disease progression according to the
Lugano classification,15 the commencement of new therapy for lymphoma, or death from any cause), as assessed
by blinded central review, among 180 patients in the
axi-cel group and 179 in the standard-care group. Patients who did not meet the criteria for an event had
their data censored (tick marks) (see the Supplementary
Methods section). In the axi-cel group, 108 patients
had an event; 82 (76%) had progression, 11 (10%) had
a change in therapy, 11 (10%) died, and 4 (4%) had a
best response of stable disease up to and including the
day 150 assessment after randomization. In the standard-care group, 144 patients had an event; 75 (52%)
had progression, 63 (44%) had a change in therapy,
and 6 (4%) died. Panel B shows the subgroup analysis
of event-free survival for key baseline and clinical covariates, including response to first-line therapy and the
second-line age-adjusted International Prognostic Index
(IPI) at randomization. The second-line age-adjusted
IPI is used to assess prognostic risk on the basis of various factors after adjustment for patient age and extranodal status at the time of diagnosis of refractory disease; risk categories are assessed as low (0 factors),
intermediate (1 factor), or high (2 or 3 factors). Hazard
ratios were formed from baseline covariates (see the
Supplementary Methods section). The 95% confidence
intervals were calculated with the use of the Clopper–
Pearson method and are not adjusted for multiplicity
and thus should not be used for inference. The hazard
ratio for the unclassified molecular subgroup could not
be estimated owing to the small sample size. DLBCL
denotes diffuse large B-cell lymphoma, and HGBL highgrade B-cell lymphoma.

with CAR T cells remaining detectable in 12 of
30 patients (40%) who could be evaluated by 24
months. The CAR T-cell peak and area under the
curve within the first 28 days after treatment
correlated with response (data not shown), findings that were consistent with those observed
in the ZUMA-1 study.18 No occurrences of anti–
axi-cel antibodies were confirmed.

Discussion
The prognosis for patients with relapsed or refractory large B-cell lymphoma after the receipt
of first-line therapy remains poor, with most
patients unable to receive definitive therapy with
high-dose chemotherapy and autologous stemcell transplantation.4,6,7 In this international,
randomized, phase 3 trial of axi-cel as compared

n engl j med 386;7

with second-line standard care in patients with
early relapsed or refractory large B-cell lymphoma, we observed a clear improvement with
axi-cel, as compared with standard care, in
event-free survival and the percentage of patients
with a response. Event-free survival is a widely
accepted, robust early efficacy end point in
clinical trials involving patients with large B-cell
lymphoma, on the basis of retrospective analyses of randomized trials that have shown a correlation between improvements in event-free
survival and overall survival.19-21 Patients with
relapsed or refractory large B-cell lymphoma
who do not have a response to salvage chemotherapy (i.e., who have progressive or stable
disease) will not benefit from high-dose chemotherapy with autologous stem-cell transplantation.22 In this scenario, a change to third-line
therapy is indicated, sometimes in the absence
of progressive disease.6 These reasons underscore why event-free survival is an important end
point for this trial.
Axi-cel therapy was superior to standard care
with a median event-free survival that was longer
by a factor of more than 4, a 2-year event-free
survival that was higher by a factor of 2.5, a
significantly higher percentage of patients with
a response, and double the percentage of patients with a complete response. Event-free survival outcomes with standard care in this trial
were consistent with those that have been observed in patients with refractory or early relapsed disease who were receiving second-line
therapy in the post-rituximab era.4,6,7 Treatment
with axi-cel also led to longer event-free survival
than standard care across key subgroups, including patients with high-risk features, such as
high-grade B-cell lymphoma (including doubleor triple-hit lymphomas) and an age of 65 years
or more, although further improvements in these
subgroups are needed.23 Although 30% of the
patients in our trial were 65 years of age or
older, elderly patients may not qualify for transplantation in certain regions of the world.24,25
This trial showed that axi-cel can be an effective
second-line therapeutic option in elderly patients
who do not have clinically significant coexisting
conditions.
The difference in overall survival between the
two groups did not reach statistical significance.
Patients who had disease progression or lack of
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A Overall Survival
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Standard care
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Axi-cel
Standard Care
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NR (28.3–NE)
35.1 (18.5–NE)

Stratified hazard ratio for death,
0.73 (95% CI, 0.53–1.01)
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Overall
Survival
(95% CI)

Axi-cel

60

0

2

4

6

8

10

12

14

16

18

20

22

24

26

28

30

32

34

36
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33
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7

5
4

2
1

0
0

Months
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Axi-cel
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Standard care 179 171 161 148 133 120 109 104 100 91 74

B Progression-free Survival
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35
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33
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Figure 3. Overall Survival and Progression-free Survival.
Panel A shows the Kaplan–Meier estimate of overall survival, and Panel B the Kaplan–Meier estimate of progression-free survival as assessed by the investigator. The 95% confidence intervals were not adjusted for multiplicity and should not be used for inference. NE denotes could not be estimated, and NR not reached.

response in the standard-care group could receive CAR T-cell therapy outside the protocol
(which occurred in 56% of the patients), which
may have confounded the analysis of overall
survival, as suggested by the results of the prespecified sensitivity analyses (Fig. S3). The median overall survival in the standard-care group was
longer than has been observed in historical studies7,26; this finding is potentially due to the availability of newer agents, such as CAR T-cell therapy, that can be used in patients whose disease is
refractory to or relapses after second-line therapy.
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Although nearly all the patients who had been
randomly assigned to the axi-cel group received
an infusion of axi-cel, only a minority of patients
(36%) in the standard-care group received highdose chemotherapy with autologous stem-cell
transplantation; this percentage is consistent
with findings in historical studies, especially
those with high proportions of patients with
primary refractory disease and early relapse and
of patients who had received rituximab previously (Table S11).4,7,26 Given that it is not known
a priori which patients will have a response to
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salvage therapy, and because the majority of
patients do not receive definitive therapy with
high-dose chemotherapy and autologous stemcell transplantation, outcomes with the current
standard-care therapy are poor. By design, the
ZUMA-7 trial randomly assigned patients to
groups before the receipt of salvage chemoimmunotherapy and showed that avoidance of salvage chemoimmunotherapy and earlier use of
CAR T-cell therapy could result in improvements
in event-free survival and response.
The adverse-event profile of axi-cel in this
trial included high-grade events, a finding consistent with other studies of intensive treatment
for refractory large B-cell lymphoma.13,27 The
frequency of adverse events, including those of
grade 3 or higher and of serious adverse events,
was high in the two treatment groups, although
the adverse-event profile differed between the
two groups, with the incidence of cytokine release syndrome and neurologic events being
higher in the axi-cel group.
In this trial, bridging therapy was restricted to
glucocorticoids to avoid the progression of lymphoma during the axi-cel manufacturing process and to isolate the effects of CAR T-cell
therapy as second-line therapy. Although this
approach potentially limited the enrollment of
patients for whom urgent therapy was indicated,
enrolled patients had aggressive disease, with
74% of the patients having primary refractory
disease. Prohibition of the use of chemotherapy
bridging, which could alone result in 40 to 50%
of patients having a response,4,7,26 ensured that the
results in the axi-cel group were not confounded.
In the real world, however, bridging chemotherapy may sometimes need to be started urgently.
In patients who received and had a response
to salvage chemoimmunotherapy and thus were
able to proceed to high-dose chemotherapy with
autologous stem-cell transplantation, outcomes
were not as poor. Although the duration of response was numerically favorable for axi-cel, the
95% confidence interval was broad and consistent with the possibility of no effect (Fig. S4).
Nevertheless, because chemosensitivity is unknown before the initiation of treatment, the
use of axi-cel as second-line therapy may avoid
additional chemotherapy in patients who would
ultimately not receive a transplant, may shorten
the time to definitive therapy, and may avoid
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both the risk of clinical deterioration and the
potential effect on CAR T-cell fitness with more
numerous previous lines of therapy.28
Not all patients benefited from axi-cel as
second-line therapy. The ZUMA-7 trial has some
limitations, including the lack of examination of
CD19 expression on progressive tumors, determination of whether CAR T cells reexpand in
blood at progression, ex vivo evaluation of CAR
T-cell function at progression, or elucidation of
resistance mechanisms associated with tumor
size or inflammation.29-31 Additional correlative
analyses are necessary to determine markers of
response durability and mechanisms of resistance. Given that it remains unclear which
therapies may be useful in patients who have a
relapse after the receipt of axi-cel, these additional data, together with real-world outcomes
and clinical trials, may help inform treatment
decisions in the future.32
Whereas the majority of patients with large
B-cell lymphoma have a relapse less than 12
months after the receipt of induction therapy in
the post-rituximab era,33,34 this trial did not enroll patients with large B-cell lymphoma relapse
that occurred more than 12 months after the
receipt of induction therapy. Relapses occurring
later after induction therapy are generally associated with a greater probability of response to
second-line therapy. However, the 2-year eventfree survival of 41% among patients with refractory or early relapsed disease in the axi-cel
group compares favorably with that in previous
phase 3 trials4,7 involving patients receiving standard care who had received rituximab previously
and had later disease relapse (>12 months after
the diagnosis).
The ZUMA-7 trial showed a significant improvement in efficacy with axi-cel therapy, as
compared with second-line standard care, in
patients with relapsed or refractory large B-cell
lymphoma. Treatment with axi-cel induced highgrade adverse events in the vast majority of patients, but few patients had fatal effects from
treatment and the magnitude of the toxicity was
consistent with previous reports in third-line
therapy, although unique problems attend CAR
T-cell therapy.13 Axi-cel appears to be a viable
alternative to a regimen of chemoimmunotherapy, high-dose chemotherapy, and autologous
stem-cell transplantation for the second-line
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Table 2. Most Common Adverse Events, Cytokine Release Syndrome, and Neurologic Events.*
Axi-cel
(N = 170)

Event

Any adverse event — no. (%)

Standard Care
(N = 168)

Any Grade

Grade ≥3

Any Grade

Grade ≥3

170 (100)

155 (91)

168 (100)

140 (83)

Pyrexia

158 (93)

15 (9)

43 (26)

1 (1)

Neutropenia†

121 (71)

118 (69)

70 (42)

69 (41)

Hypotension

75 (44)

19 (11)

25 (15)

5 (3)

Fatigue

71 (42)

11 (6)

87 (52)

4 (2)

Anemia

71 (42)

51 (30)

91 (54)

65 (39)

Diarrhea

71 (42)

4 (2)

66 (39)

7 (4)

Headache

70 (41)

5 (3)

43 (26)

2 (1)

Nausea

69 (41)

3 (2)

116 (69)

9 (5)

Sinus tachycardia

58 (34)

3 (2)

17 (10)

1 (1)

Leukopenia‡

55 (32)

50 (29)

43 (26)

37 (22)

Thrombocytopenia§

50 (29)

25 (15)

101 (60)

95 (57)

Chills

47 (28)

1 (1)

14 (8)

0

Hypokalemia

44 (26)

10 (6)

49 (29)

11 (7)

Hypophosphatemia

45 (26)

31 (18)

29 (17)

21 (12)

Cough

42 (25)

1 (1)

18 (11)

0

Decreased appetite

42 (25)

7 (4)

42 (25)

6 (4)

Hypoxia

37 (22)

16 (9)

13 (8)

7 (4)

Dizziness

36 (21)

2 (1)

21 (12)

1 (1)

Constipation

34 (20)

0

58 (35)

0

Vomiting

33 (19)

0

55 (33)

1 (1)

4 (2)

4 (2)

46 (27)

46 (27)

157 (92)

11 (6)

—

—

155/157 (99)

14/157 (9)

—

—

68/157 (43)

18/157 (11)

—

—

Sinus tachycardia — no./total no. (%)

49/157 (31)

3/157 (2)

—

—

Chills — no./total no. (%)

38/157 (24)

0/157

—

—

Hypoxia — no./total no. (%)

31/157 (20)

13/157 (8)

—

—

Headache — no./total no. (%)

32/157 (20)

2/157 (1)

—

—

Febrile neutropenia
Cytokine release syndrome — no. (%)
Pyrexia — no./total no. (%)
Hypotension — no./total no. (%)

Neurologic event — no. (%)

102 (60)

36 (21)

33 (20)¶

1 (1)

Tremor

44 (26)

2 (1)

1(1)

0
0

Confusional state

40 (24)

9 (5)

4 (2)

Aphasia

36 (21)

12 (7)

0

0

Encephalopathy

29 (17)

20 (12)

2 (1)

0

Paresthesia

8 (5)

1 (1)

14 (8)

0

Delirium

3 (2)

3 (2)

5 (3)

1 (1)

*	Shown are any adverse events of any grade that occurred in at least 20% of the patients in either the axi-cel group or the
standard care-group, as well as events of the cytokine release syndrome that occurred in at least 15% of the patients in
the axi-cel group and neurologic events of any grade that occurred in at least 15% of the patients in the axi-cel group or
at least 3% of those in the standard-care group. The severity of the cytokine release syndrome was graded according to
Lee et al.14 Neurologic events were identified with the use of prespecified search list of preferred terms in the Medical
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Table 2. (Continued.)
Dictionary for Regulatory Activities, version 23.1, on the basis of known neurotoxic effects associated with anti-CD19 immu
notherapy, and were specifically identified with the use of methods that were based on the phase 2 study of blinatumomab.17
The severity of all adverse events, including neurologic events and symptoms of the cytokine release syndrome, was graded with the use of the Common Terminology Criteria for Adverse Events, version 4.03, of the National Cancer Institute.
†	Neutropenia refers to the combined preferred terms of neutropenia and neutrophil count decreased.
‡	Leukopenia refers to the combined preferred terms of leukopenia and white-cell count decreased.
§	Thrombocytopenia refers to the combined preferred terms of thrombocytopenia and platelet count decreased.
¶	Other preferred terms that were reported in one or two patients in the standard-care group included somnolence, agitation, hypoesthesia, lethargy, depressed level of consciousness, cognitive disorder, memory impairment, bradyphrenia,
taste disorder, hallucination, visual hallucination, nystagmus, head discomfort, and neuralgia.

treatment of relapsed or refractory large B-cell
lymphoma.
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